~~<i id='6CC98F53E0'><strike id='6CC98F53E0'><tt id='6CC98F53E0'><pre id='6CC98F53E0'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：comprehensive 2025-08-03 16:33:27 Page View：3

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA weighs limits of animal data in assessing artificial wombs
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Did the public have the right to know Arthur Ashe had AIDS?

ArthurAshecompetinginLondonin1968.HultonArchive/GettyImagesDoprominentpublicfigureswhoareillhavesome

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Bacterial infection may be ‘key event’ in endometriosis, study says

AnewstudydocumentshowFusobacteriummightspurthedevelopmentofendometriosis.V.R.Dowell/CDCEndometriosis